



11th MIWGUC meeting (Barcelona 2025)

Developing best outcome measures to use in a 12 month clinical trial to assess effectivity of a drug

Dates: 23-24th of January 2025

Venue: Hotel Room Mate Carla (Carrer de Mallorca 288, 08037 Barcelona)

Free Registration

Organized by: Fundació Privada per la Recerca i la Docència Sant Joan de Déu (CIF: G62978689)

Director: Jordi Antón and Ivan Foeldvari

THURSDAY, 23th January 2025

17.00- 19.30: Welcome

Session 1:

- Summary of MIWGUC activities (20 min + 10 min discussion)
 - Ivan Foeldvari
- Results and outcome measures of a weaning trial in uveitis related JIA (20 min + 10 min discussion)
 - Nisha Acharya
- Phase II/III trials in uveitis related JIA and chronic anterior uveitis
 - Do we used the right inclusion criteria?
 - Ivan Foeldvari
 - View of a biostatistician; which are the best responding outcome measures?
 - Jens Klotsche
- Group discussion (40 min)

Dinner together (invitation by the Sant Joan de Déu team)



FRIDAY, 24th January 2025

09.00- 13.00: Session 2:

- Quality of life measure for uveitis clinical trials: EYE-QL development (20 min)
 - Sheila Angeles-Han
- Literature review in outcome measures for uveitis trials beyond phase III clinical trials
 - Pediatric Rheumatology view: Gabriele Simonini (20 min)
 - Ophthalmologist view: Harry Petrushkin (20 min)
- Biomarkers for clinical trials (20 min)
 - Lola Solebo

10.30- 11.00 coffee break

11:00 – 13:00

- Patients' perspective in clinical trials (15 min)
 - Jan Titz
- Young patients advisory group (KIDS-Barcelona) (15 min)
 - *Barcelona patient*
- How can we use existing trial data to look effectiveness of new drugs in Juvenile idiopathic arthritis and rare diseases (30 min)
 - Nicola Ruperto
- Group discussion (30 min)
- New drugs effectivity regarding uveitis in phase III Juvenile idiopathic arthritis trials: Companies representatives are asked to present their data (each 10 min)
 - Baricitinib and Ixekizumab (Jens Gammelftoft Gerwien, Lilly)
 - Upadacitinib (Ana B. Romero, abbvie)
 - Tofacitinib (Pfizer)
 - Secukinumab (Novartis)



Lunch break 13.30-14.30

14.30-19.00: Session 3: *(including coffee break 16.30-17:00)*

- Consensus about best clinical outcome measures to use in 12 months trial
 - Ivan Foeldvari
- Development of Treatment plans for uveitis related JIA and Chronic anterior uveitis
 - All together

19:00- 19:30: Summary and Next steps



List of invited MIWGUC members:

Pediatric rheumatologists:

- Sheila Angeles-Han: Sheila.Angeles-Han@cchmc.org
- Jordi Antón: jordi.anton@sjd.es
- Tamás Constantin: tamas.constantin@gmail.com
- Ivan Foeldvari: foeldvari@t-online.de
- Mia Glerup: miagleru@rm.dk
- Helen Ingels: helene.andrea.sinclair.ingels.02@regionh.dk
- Ellen Nordal: Ellen.Berit.Nordal@unn.no
- Gabriele Simonini: gabriele.simonini@unifi.it
- Joost Swart: J.F.Swart@umcutrecht.nl

Ophthalmologists:

- Nisha Acharya : nisha.acharya@ucsf.edu
- Regitze Bangsgaard: regitze.bangsgaard@regionh.dk
- Joke de Boer: jboer@umcutrecht.nl
- Jesús Díaz Cascajosa: jesus.diaz@sjd.es
- Viera Koopman-Kalinina Ayuso: v.kalininaayuso@umcutrecht.nl
- Charlotte van Meerwijk: c.l.i.i.van.meerwijk@umcg.nl
- Elisabetta Miserocchi: miserocchi.elisabetta@hsr.it
- Harry Petrushkin: h.petrushkin@nhs.net
- Lola Solebo: a.solebo@ucl.ac.uk
- Nicole Stübiger: n.stuebiger@uke.de

Statistician:

- Jens Klotsche: Jens.Klotsche@drfz.de

Invited speakers:

- Nicola Ruperto: nicolaruperto@outlook.it

Industry representatives:

- Jens Gammeltoft Gerwien (Lilly): jggerwien@lilly.com
- Ana B. Romero (abbvie): ana.romero@abbvie.com

Patients' representatives:

- Stephanie Mata: smata82@gmail.com
- Jan Titz: jan.titz@gmx.de
- Sebastian Kramer: SebastianKramer1@gmx.de
- *Barcelona representative:*